Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles

International Journal of Oncology

Volumn 43, Issue 3, 2013, Pages 919-926

  Aftimos, Philippe G ^a   Wiedig, Murielle ^a   Fontsa, Mireille Langouo ^a   Awada, Ahmad ^a   Ghanem, Ghanem ^a   Journe, Fabrice ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Cell proliferation; Melanoma cell lines; Mutation; Protein kinase inhibitor; Signalling pathway

Indexed keywords

B RAF KINASE; JANUS KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR;

ARTICLE; CONCENTRATION (PARAMETERS); GENE MUTATION; HUMAN; HUMAN CELL; IC 50; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOXICITY; WILD TYPE;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASES; MAP KINASE KINASE KINASES; MELANOMA; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TRANSCRIPTOME;

EID: 84880615410     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2008     Document Type: Article

References (41)

1. Rokuhara S, Saida T, Oguchi M, Matsumoto K, Murase S and Oguchi S: Number of acquired melanocytic nevi in patients with melanoma and control subjects in Japan: Nevus count is a significant risk factor for nonacral melanoma but not for acral melanoma. J Am Acad Dermatol 50: 695-700, 2004.
2. Miller AJ and Mihm MC Jr: Melanoma. N Engl J Med 355: 51-65, 2006.
3. Berwick M, Erdei E and Hay J: Melanoma epidemiology and public health. Dermatol Clin 27: 205-214, viii, 2009.
4. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL and Chanmugam A: Cutaneous malignant melanoma. Mayo Clin Proc 81: 500-507, 2006.
5. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010.
6. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012.
7. Sosman JA, Kim KB, Schuchter L, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707-714, 2012.
8. Falchook GS, Long GV, Kurzrock R, et al: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379: 1893-1901, 2012.
9. Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367: 107-114, 2012.
10. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
11. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819, 2010.
12. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011.
13. Christensen C and Guldberg P: Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF. Oncogene 24: 6292-6302, 2005.
14. Montagut C, Sharma SV, Shioda T, et al: Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68: 4853-4861, 2008.
15. Johannessen CM, Boehm JS, Kim SY, et al: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-972, 2010.
16. Wagle N, Emery C, Berger MF, et al: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29: 3085-3096, 2011.
17. Poulikakos PI, Persaud Y, Janakiraman M, et al: RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480: 387-390, 2011.
18. Yancovitz M, Litterman A, Yoon J, et al: Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. PLoS One 7: e29336, 2012.
19. Tsao H, Zhang X, Benoit E and Haluska FG: Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16: 3397-3402, 1998.
20. Tsao H, Goel V, Wu H, Yang G and Haluska FG: Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122: 337-341, 2004.
21. Cheung M, Sharma A, Madhunapantula SV and Robertson GP: Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 68: 3429-3439, 2008.
22. Niu G, Bowman T, Huang M, et al: Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21: 7001-7010, 2002.
23. Byers LA, Sen B, Saigal B, et al: Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 15: 6852-6861, 2009.
24. Ji Z, Flaherty KT and Tsao H: Molecular therapeutic approaches to melanoma. Mol Aspects Med 31: 194-204, 2010.
25. Yurkovetsky ZR, Kirkwood JM, Edington HD, et al: Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13: 2422-2428, 2007.
26. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2011.
27. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367: 1694-1703, 2012.
28. Das Thakur M, Salangsang F, Landman AS, et al: Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494: 251-255, 2013.
29. Held MA, Langdon CG, Platt JT, et al: Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 3: 52-67, 2013.
30. Smalley KS: A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 104: 527-532, 2003.
31. Garnett MJ and Marais R: Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6: 313-319, 2004.
32. Gray-Schopfer VC, Cheong SC, Chong H, et al: Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 95: 496-505, 2006.
33. Michaloglou C, Vredeveld LC, Soengas MS, et al: BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436: 720-724, 2005.
34. Pollock PM, Harper UL, Hansen KS, et al: High frequency of BRAF mutations in nevi. Nat Genet 33: 19-20, 2003.
35. Dhomen N, Reis-Filho JS, da Rocha Dias S, et al: Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15: 294-303, 2009.
36. Wellbrock C, Karasarides M and Marais R: The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5: 875-885, 2004.
37. Gopal YN, Deng W, Woodman SE, et al: Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70: 8736-8747, 2010.
38. Solit DB and Rosen N: Resistance to BRAF inhibition in melanomas. N Engl J Med 364: 772-774, 2011.
39. Villanueva J, Vultur A, Lee JT, et al: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695, 2010.
40. Flaherty KT and Smalley KS: Preclinical and clinical development of targeted therapy in melanoma: attention to schedule. Pigment Cell Melanoma Res 22: 529-531, 2009.
41. Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK and Einarson TR: Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev 33: 665-680, 2007.